DelveInsight’s, “Corneal Ulcer Pipeline Insight 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Corneal Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Corneal Ulcer Pipeline. Dive into DelveInsight’s comprehensive report today! @ Corneal Ulcer Pipeline Outlook

 

Key Takeaways from the Corneal Ulcer Pipeline Report

• May 2024:- Dompé Farmaceutici S.p.A- A Prospective, Multicenter Trial to Evaluate Efficacy and Safety of Cenegermin-bkbj (20 mcg/mL) Ophthalmic Solution on Corneal Thickness Via Anterior Segment Optical Coherence Tomography (AS-OCT) in Stage 3 Neurotrophic Keratitis.
• DelveInsight’s Corneal Ulcer pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Corneal Ulcer treatment.
• The leading Corneal Ulcer Companies such as OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc, Dobecure, Editas Medicine, and others.
• Promising Corneal Ulcer Therapies such as OXERVATE® 0.002%, Riboflavin 0.25% TE Solution, and others.

 

Stay ahead with the most recent pipeline outlook for Corneal Ulcer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Corneal Ulcer Treatment Drugs

 

Corneal Ulcer Emerging Drugs Profile

• Poliesanide: Sifi S.p.A

Poliesanide is being developed by Sifi for the treatment of Acanthamoeba Keratitis. It is currently in phase III stage of development.

• CODA001: OcuNexus Therapeutics

CODA001 is an antisense oligonucleotide that down regulates the expression of the gap junction protein Cx43 which is increased in persistent epithelial defects. The first use in patients with persistent epithelial defects was reported by Ormonde et al. Five eyes with severe ocular surface burns, which were unresponsive to established therapy, were treated by connexin43-specific antisense oligodeoxynucleotide delivered in cold, thermo reversible Poloxamer407 gel under either amniotic membrane graft or bandage contact lens. The treatment reduced inflammation within 1-2 days, and complete corneal reepithelialization was obtained in all eyes. The drug was initially being developed by CODA therapeutics and after the acquisition OcuNexus Therapeutics is further developing the drug in phase II stage of development.

• Synthetic inhibitors of fibroblast growth factor (FGF): Dobecure

Dobecure is working on preclinical and clinical studies in disorders where the synthetic inhibitors of fibroblast growth factor (FGF) might be involved, such us age-related macular degeneration, both wet and dry, uveitis, corneal edema and herpetic Keratitis, tendinitis and tendinosis, cold sores, otitis and allergic rhinitis. As per the company pipeline, it is currently in Phase I stage of development.

• TTHX1114: Trefoil Therapeutics

TTHX1114 eye drops to reduce the duration and impact of ocular, herpes virus related ulcers (herpetic keratopathy), and other corneal ulcers. Trefoil is developing a topical (eye drop) version of TTHX1114 for herpes-induced corneal ulcers to accelerate corneal wound healing, stimulate epithelial cell growth and reduce complications such as pain and inflammation. Topical TTHX1114 has potential to complement the use of other treatments for the underlying infection, such as antiviral drugs and surgery. In preclinical studies, the TTHX1114 significantly reduced corneal damage in animal models of herpetic keratopathy. The topical formulation is expected to enter clinical trials in 2022.

 

Explore groundbreaking therapies and clinical trials in the Corneal Ulcer Pipeline. Access DelveInsight’s detailed report now! @ New Corneal Ulcer Drugs

 

Corneal Ulcer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Infusion
• Intradermal
• Intramuscular
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

 

Corneal Ulcer Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

 

Unveil the future of Corneal Ulcer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Corneal Ulcer Market Drivers and Barriers

 

Scope of the Corneal Ulcer Pipeline Report

• Coverage- Global
• Corneal Ulcer Companies- OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc, Dobecure, Editas Medicine, and others.
• Corneal Ulcer Therapies- OXERVATE® 0.002%, Riboflavin 0.25% TE Solution, and others.
• Corneal Ulcer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Corneal Ulcer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Corneal Ulcer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Corneal Ulcer Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Corneal Ulcer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Corneal Ulcer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Corneal Ulcer Collaboration Deals
9. Late Stage Products (Phase III)
10. Poliesanide: Sifi S.p.A
11. Mid Stage Products (Phase II)
12. CODA001: OcuNexus Therapeutics
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. Synthetic inhibitors of fibroblast growth factor (FGF): Dobecure
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. TTHX1114: Trefoil Therapeutics
19. Inactive Products
20. Corneal Ulcer Key Companies
21. Corneal Ulcer Key Products
22. Corneal Ulcer- Unmet Needs
23. Corneal Ulcer- Market Drivers and Barriers
24. Corneal Ulcer- Future Perspectives and Conclusion
25. Corneal Ulcer Analyst Views
26. Corneal Ulcer Key Companies
27. Appendix

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/